JPWO2021142477A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021142477A5 JPWO2021142477A5 JP2022542380A JP2022542380A JPWO2021142477A5 JP WO2021142477 A5 JPWO2021142477 A5 JP WO2021142477A5 JP 2022542380 A JP2022542380 A JP 2022542380A JP 2022542380 A JP2022542380 A JP 2022542380A JP WO2021142477 A5 JPWO2021142477 A5 JP WO2021142477A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- disorder
- neuroactive steroid
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003431 steroids Chemical class 0.000 claims 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 229910052805 deuterium Inorganic materials 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 208000005809 status epilepticus Diseases 0.000 claims 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 4
- 206010003805 Autism Diseases 0.000 claims 4
- 208000020706 Autistic disease Diseases 0.000 claims 4
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 208000001914 Fragile X syndrome Diseases 0.000 claims 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000029560 autism spectrum disease Diseases 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 201000009916 Postpartum depression Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000022821 personality disease Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- -1 2 -cyclopropyl Chemical group 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000009575 Angelman syndrome Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 208000009205 Tinnitus Diseases 0.000 claims 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- 208000009443 Vascular Malformations Diseases 0.000 claims 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 201000006145 cocaine dependence Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 201000006517 essential tremor Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 2
- 201000005040 opiate dependence Diseases 0.000 claims 2
- 208000022610 schizoaffective disease Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 230000000946 synaptic effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 231100000886 tinnitus Toxicity 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 1
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 claims 1
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000024823 antisocial personality disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959977P | 2020-01-12 | 2020-01-12 | |
| US62/959,977 | 2020-01-12 | ||
| PCT/US2021/013112 WO2021142477A1 (en) | 2020-01-12 | 2021-01-12 | Neuroactive steroids and pharmaceutical composition containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509798A JP2023509798A (ja) | 2023-03-09 |
| JP2023509798A5 JP2023509798A5 (https=) | 2024-01-19 |
| JPWO2021142477A5 true JPWO2021142477A5 (https=) | 2024-01-19 |
Family
ID=76788885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542380A Pending JP2023509798A (ja) | 2020-01-12 | 2021-01-12 | ニューロアクティブステロイド、及びニューロアクティブステロイドを含む医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230118577A1 (https=) |
| EP (1) | EP4087854A4 (https=) |
| JP (1) | JP2023509798A (https=) |
| KR (1) | KR20230031812A (https=) |
| CN (1) | CN115244065B (https=) |
| AU (1) | AU2021206712A1 (https=) |
| BR (1) | BR112022013585A2 (https=) |
| CA (1) | CA3167331A1 (https=) |
| IL (1) | IL294606A (https=) |
| MX (1) | MX2022008614A (https=) |
| WO (1) | WO2021142477A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202112111WA (en) | 2019-05-10 | 2021-11-29 | Brii Biosciences Inc | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof |
| CR20240234A (es) * | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| TW202143976A (zh) * | 2020-03-18 | 2021-12-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| CN115974950A (zh) * | 2022-12-23 | 2023-04-18 | 上海彩迩文生化科技有限公司 | 一种3-烷基化的甾体中间体及其制备和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1359646A (fr) * | 1962-11-22 | 1964-04-30 | Roussel Uclaf | Procédé de préparation de dérivés stéroïdes et produits obtenus par ce procédé |
| NL6808141A (https=) * | 1967-06-16 | 1968-12-17 | ||
| GB1409239A (en) * | 1971-11-11 | 1975-10-08 | Glaxo Lab Ltd | Process for the preparation of 3alpha-hydroxy-5alpha-steroids |
| HK1258616A1 (zh) * | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| MA45599A (fr) * | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| CR20240234A (es) * | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| MX2022010620A (es) * | 2020-02-27 | 2022-11-30 | Brii Biosciences Inc | Profarmacos de esteroides neuroactivos. |
-
2021
- 2021-01-12 WO PCT/US2021/013112 patent/WO2021142477A1/en not_active Ceased
- 2021-01-12 CA CA3167331A patent/CA3167331A1/en active Pending
- 2021-01-12 US US17/792,319 patent/US20230118577A1/en not_active Abandoned
- 2021-01-12 JP JP2022542380A patent/JP2023509798A/ja active Pending
- 2021-01-12 EP EP21738878.4A patent/EP4087854A4/en active Pending
- 2021-01-12 KR KR1020227027899A patent/KR20230031812A/ko active Pending
- 2021-01-12 IL IL294606A patent/IL294606A/en unknown
- 2021-01-12 BR BR112022013585A patent/BR112022013585A2/pt unknown
- 2021-01-12 AU AU2021206712A patent/AU2021206712A1/en active Pending
- 2021-01-12 MX MX2022008614A patent/MX2022008614A/es unknown
- 2021-01-12 CN CN202180020110.2A patent/CN115244065B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519267A5 (https=) | ||
| JP2017531020A5 (https=) | ||
| JP2018505898A5 (https=) | ||
| JP2018508592A5 (https=) | ||
| JP2018104454A5 (https=) | ||
| JP2014526469A5 (https=) | ||
| RU2016105971A (ru) | Применение флекаинида в качестве антиконнексинового средства и способ потенцирования эффектов психотропных лекарственных средств | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| JP2007500757A5 (https=) | ||
| JP2009527462A5 (https=) | ||
| JPWO2021142477A5 (https=) | ||
| RU2007119585A (ru) | Производные рапамицина и их применение при лечении неврологических заболеваний | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2020517607A5 (https=) | ||
| RU2018140250A (ru) | Пролекарство производного аминокислоты | |
| BR112015027362A8 (pt) | derivados de isoquinolina estimulantes de neurogênese | |
| JP2021527636A5 (https=) | ||
| JPWO2022040545A5 (https=) | ||
| JP2019532983A5 (https=) | ||
| JPWO2020132474A5 (https=) | ||
| JP2017502069A5 (https=) | ||
| RU2016132574A (ru) | Органические соединения | |
| JPWO2020111268A5 (https=) | ||
| JPWO2019246300A5 (https=) | ||
| JPWO2020249796A5 (https=) |